Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version
For patients with Lung cancer; a FACT-Lung Symptom Index (a subset of FACT-L containing 12 items)
Below are the details for the FLSI-12 measure:
Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version (FLSI-12)
NUMBER OF ITEMS:
Lung cancer patients 18 years and older
Past 7 days
5 point Likert-type scale
Paper and electronic
Self-administration and interview when applicable
Lung cancer symptom index
TIME FOR COMPLETION:
Less than 5 minutes
Manual scoring template, some items are reverse scored. Total scores possible.
Available translations of the FLSI-12 can be obtained by registering for permission. Users are not permitted to translate the FLSI-12 without permission from FACIT.org. Permission from FACIT.org to translate the FLSI-12 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366.
Cella, D., Eton, D., Hensing, T., Masters, G., & Parasuraman, B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clinical Lung Cancer 2008; 9(1): 51-58. doi: 10.3816/CLC.2008.n.009.
Yount, S., Rothrock, N., Bass, M., Beaumont, J., Pach, D., Lad, R., Patel, J., Corona, M., Weiland, R., Del, K., & Cella, D. A randomized trial of weekly symptom telemonitoring in advanced lung cancer. Journal of Pain and Symptom Management 2014; 47(6): 973-989. doi: 10.1016/j.jpainsymman.2013.07.01.
Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.
Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.
Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.
Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.